Exact Sciences Sees Growth in Tests
Exact Sciences recently announced its third quarter numbers, which included revenue of $118.3 million and 240,000 completed Cologuard tests, an increase of 63 percent and 49 percent, respectively. “The Exact…
Category Archives: Biotech
Exact Sciences Acquires Biomatrica
Exact Sciences strengthened its pipeline capabilities with its acquisition of Biomatrica, a provider of biological sample preservation technology, the company announced today. “To detect cancer at its earliest stages, you need…
Report Shows Biohealth Impact in WI
In 2017, the biohealth industry in Wisconsin contributed $48 billion in economic output and $1.3 billion in total state and local taxes, according to the Wisconsin Biohealth Industry 2018 Economic Impact…
Cellectar’s CLR 131 Receives Fourth RPDD
Cellectar Biosciences’ CLR 131 has been granted a Rare Pediatric Disease Designation (RPDD) for the treatment of osteosarcoma, the company announced recently. “Cellectar is pleased to have the opportunity to…
Phoenix to Build Facility in Fitchburg
Phoenix, which designs and manufactures the world’s strongest neutron generators, is building a neutron imaging center in Fitchburg, Wis., the company announced recently. According to a release, the 10,000-square foot building,…
Exact Sciences, Pfizer Form Agreement
Exact Sciences and Pfizer announced today an agreement to co-promote Cologuard through 2021. According to a release, Pfizer will join Exact Sciences’ sales representatives in reaching both physicians and health…
Propeller Health, Anthem Collaborate
Propeller Health announced recently that it’s collaborating with Anthem Blue Cross and Blue Shield to help improve health outcomes for Ohio consumers enrolled in Anthem’s Medicare Advantage health plans who have…
Exact Sciences Breaks Ground at Innovation One
Exact Sciences broke ground on its new corporate headquarters building at University Research Park, calling it Innovation One, the company announced recently. According to a release, the 138,000 square-foot building,…
Cellectar’s CLR 131 Receives RPDD
Cellectar Biosciences’ CLR 131 has been granted a Rare Pediatric Disease Designation (RPDD) for the treatment of Ewing’s sarcoma, a rare pediatric cancer, by The U.S. Food and Drug Administration…
Cellectar Closes $16.56M Public Offering
Cellectar Biosciences today announced the effective prices of $4.00 per share of common stock of an underwritten public offering to raise approximately $16.56 million. According to a release, this includes the full…
